Details
Stereochemistry | ACHIRAL |
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca]
InChI
InChIKey=FAQLAUHZSGTTLN-UHFFFAOYSA-N
InChI=1S/Ca.2H
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. | 2001 Aug 28 |
|
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001 Dec 21 |
|
Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
[Acute renal failure caused by hypercalcemia]. | 2001 Jun 10 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001 Nov |
|
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001 Oct 12 |
|
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. | 2001 Sep |
|
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. | 2001 Sep 1 |
|
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein. | 2001 Sep 15 |
|
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002 Feb |
|
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002 Jul |
|
Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002 Jul 5 |
|
Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
Henri Moissan: winner of the Nobel Prize for Chemistry 1906. | 2006 Oct 20 |
|
Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
|
A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans. | 2012 Apr |
|
Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014 Jan 17 |
|
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:07 GMT 2025
by
admin
on
Mon Mar 31 18:13:07 GMT 2025
|
Record UNII |
SY7Q814VUP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
42857-3
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
27037-1
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
32305-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
12181-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
M05BB05
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
71790-0
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NCI_THESAURUS |
C1940
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
27373-0
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
35675-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
49005-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
42593-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
9467-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
16525-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
27182-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
25583-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
CFR |
21 CFR 862.1145
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
35247-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000006512
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
50839-0
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
1998-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
27091-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
57335-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
16273-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
14636-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
30527-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000006512
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
74516-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
14637-3
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
A11GB01
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
2001-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000175597
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
49764-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
14418-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
12511-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000020074
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
27172-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
1996-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
2002-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
32541-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
13444-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
14417-0
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
57334-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000175901
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
49765-1
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
44716-9
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
29276-3
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
14419-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
58781-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
2003-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
2004-0
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
16518-3
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
6874-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
M05BB04
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-VATC |
QA11GB01
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
25362-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
17861-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
24518-3
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
15155-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000006512
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
38250-7
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
51610-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
54364-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
18488-7
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
9321-1
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
16526-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
57919-3
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
A11AA02
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
CFR |
21 CFR 101.72
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
53100-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
DSLD |
27 (Number of products:15496)
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
1999-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
NDF-RT |
N0000006512
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
13448-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
M05BB02
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
18186-7
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
49937-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
35246-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-VATC |
QA11AA02
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
2000-8
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
50836-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
53124-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
13717-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
54365-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
A07XA03
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
16527-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
14416-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
87477-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
59000-0
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
53502-1
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
1997-6
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
WHO-ATC |
M05BB01
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
35248-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
53455-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
||
|
LOINC |
17862-4
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
22984
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
SY7Q814VUP
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
SY7Q814VUP
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
D002118
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
CHEMBL2146121
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
100000092619
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
1086866
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
SUB13159MIG
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
1895
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | RxNorm | ||
|
Calcium
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
m2918
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID9050484
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
7440-70-2
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
273
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
29320
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
231-179-5
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
C331
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
5460341
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY | |||
|
DB01373
Created by
admin on Mon Mar 31 18:13:07 GMT 2025 , Edited by admin on Mon Mar 31 18:13:07 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|